CENTER FOR SINGLE PHOTON-EMITTING CANCER IMAGING AGENTS

单光子发射癌症成像剂中心

• 批准号: 7276668
• 负责人: Wynn A Volkert
• 金额: $ 189.64万
• 依托单位: UNIVERSITY OF MISSOURI-COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7276668
• 关键词: Affinity; Antigen Receptors; Binding; Biochemical; Biochemistry; Breast; Cell surface; Chemistry; Development; Extramural Activities; Fostering; Generations; Goals; Grant; Image; Institution; Interdisciplinary Study; Label; Malignant Neoplasms; Malignant neoplasm of lung; Missouri; Molecular Biology; Nuclear; Pancreas; Phage Display; Pharmacology; Photons; Prostate Lymphoma; Radiation therapy; Radioisotopes; Radiolabeled; Radiopharmaceuticals; Research; Research Activity; Research Design; Research Infrastructure; Research Personnel; Resources; Science; Scientific Advances and Accomplishments; Scientist; Site; Specificity; Techniques; Tumor Biology; Universities; abstracting; analog; angiogenesis; cancer cell; cancer imaging; combinatorial chemistry; comparative; design; in vivo; in vivo Cellular and Molecular Imaging Centers; melanoma; molecular imaging; novel; oncology; particle; programs; radiotracer; single photon emission computed tomography; stable plasma protein solution; uptake; vector

(Revised Abstract) DESCRIPTION (provided by applicant): The overall goal of the Center for Single Photon-Emitting Cancer Imaging Agents at the University of Missouri-Columbia (MU) is to foster interdisciplinary research to enable development of novel radiolabeled molecular imaging agents capable of selective in vivo uptake and retention in cancer cells. The Research Components and Development Projects supported by this grant are primarily focused on identification of single-photon emitting, site-directed in vivo targeting biomolecular-conjugates directed to cell surface receptors, antigens and angiogenesis markers with high specificity. Many of the bioconjugates developed in this ICMIC are designed to allow corresponding analogues labeled with particle-emitting radionuclides to be produced for potential radiotherapeutic applications. Molecular biology and biochemical techniques form the primary approach for the design and generation of new cancer targeting vectors, including in vivo phage display, combinatorial chemistry/biochemistry, and SPPS. The In vivo Cellular and Molecular Imaging Center (ICMIC) grant will provide essential support to maintain current and catalyze expansion of research teams which are composed of scientists that combine expertise in molecular biology, chemistry, radiopharmaceutical chemistry, comparative oncology, pharmacology, tumor biology and nuclear imaging. The major thrust of the research that will be conducted in the ICMIC will involve the development of 99mTc-, 111In-and 123I-labeled SPECT imaging agents. The radiolabeled bioconjugates to be designed and studied will selectively bind with high affinity to a variety of cancers, including breast, pancreatic, melanoma, lymphoma, prostate and lung cancers. Specialized Resources (Cores) supported by the ICMIC provide critical infrastructure and expertise to support cross-disciplinary research activities conducted in the Research Components and the Development Projects. The ICMIC will facilitate expansion and enhance the scope and quality of radiopharmaceutical sciences research related to development of novel, highly specific cancer targeting imaging agents. The scientific advances made in this program will foster new interdisciplinary research programs with other investigators at both this and extramural institutions, including other ICMICs and Pre-ICMICs.

(修订摘要)描述(由申请人提供)：密苏里大学哥伦比亚分校(MU)单光子发射癌症显像剂中心的总体目标是促进跨学科研究，使能够在癌细胞中选择性摄取和保留的新型放射性标记分子显像剂的开发成为可能。这笔拨款支持的研究组成部分和开发项目主要集中在鉴定单光子发射、体内定位靶向针对细胞表面受体、抗原和血管生成标记物的生物分子结合物，具有高度特异性。在这种ICMIC中开发的许多生物结合物旨在允许生产相应的标记有粒子发射的放射性核素的类似物，用于潜在的放射治疗应用。分子生物学和生化技术构成了设计和产生新的肿瘤靶向载体的主要方法，包括体内噬菌体展示、组合化学/生物化学和SPPS。体内细胞和分子成像中心(ICMIC)的拨款将提供必要的支持，以维持和促进研究团队的扩大，研究团队由结合了分子生物学、化学、放射性药物化学、比较肿瘤学、药理学、肿瘤生物学和核成像专业知识的科学家组成。将在ICMIC中进行的研究的主要内容将涉及99mTc、111In和123I标记的SPECT显像剂的开发。将要设计和研究的放射性标记生物结合物将选择性地与多种癌症结合，包括乳腺癌、胰腺癌、黑色素瘤、淋巴瘤、前列腺癌和肺癌。由国际信息和通信技术中心支持的专门资源(核心)提供重要的基础设施和专门知识，以支持在研究构成部分和发展项目中开展的跨学科研究活动。ICMIC将促进与开发新的、高度特异性的癌症靶向显像剂相关的放射性制药科学研究的范围和质量的扩大和提高。该计划所取得的科学进步将促进与本机构和校外机构的其他研究人员开展新的跨学科研究计划，包括其他ICMIC和前ICMIC。

项目成果

Design, synthesis, and chemistry of sterically nondemanding primary bisphosphines.

空间要求不高的伯双膦的设计、合成和化学。

• DOI: 10.1021/ja047238y
• 发表时间: 2005
• 期刊: Journal of the American Chemical Society.
• 作者: Pillarsetty,Nagavarakishore;Raghuraman,Kannan;Barnes,CharlesL;Katti,KatteshV
• 通讯作者: Katti,KatteshV

99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection.

99mTc 和 111In 标记的 α 黑素细胞刺激激素肽作为成像探针用于原发性和肺转移性黑色素瘤检测。

• 发表时间: 2007
• 期刊: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
• 作者: Miao,Yubin;Benwell,Katherine;Quinn,ThomasP
• 通讯作者: Quinn,ThomasP

Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents.

简化人前列腺癌噬菌体颗粒的体内选择和筛选，用于开发基于肽的体内肿瘤成像剂。

• DOI: 10.2174/1386207311107010009
• 发表时间: 2011
• 期刊: Combinatorial chemistry & high throughput screening
• 影响因子: 1.8
• 作者: Newton-Northup,JessicaR;Figueroa,SaidD;Deutscher,SusanL
• 通讯作者: Deutscher,SusanL

Evaluation of a B-cell leukemia-lymphoma 2-specific radiolabeled peptide nucleic acid-peptide conjugate for scintigraphic detection of neoplastic lymphocytes in dogs with B-cell lymphoma.

评估 B 细胞白血病-淋巴瘤 2 特异性放射性标记肽核酸-肽缀合物用于闪烁显像检测患有 B 细胞淋巴瘤的狗的肿瘤性淋巴细胞。

• DOI: 10.2460/ajvr.73.5.681
• 发表时间: 2012
• 期刊: American journal of veterinary research
• 影响因子: 1
• 作者: Statham-Ringen,KimberlyA;Selting,KimberlyA;Lattimer,JimmyC;Henry,CarolynJ;Green,JonathanA;Bryan,JeffreyN;Jia,Fang;Lewis,MichaelR
• 通讯作者: Lewis,MichaelR

Corruption of phage display libraries by target-unrelated clones: diagnosis and countermeasures.

• DOI: 10.1016/j.ab.2010.07.037
• 发表时间: 2010-12-15
• 期刊: Analytical biochemistry
• 影响因子: 2.9
• 作者: Thomas WD;Golomb M;Smith GP
• 通讯作者: Smith GP